Newsroom
Sorted by: Latest
-
Blackline Safety Enters into Definitive Agreement to be Acquired by Francisco Partners for up to $850 Million
CALGARY, Canada--(BUSINESS WIRE)--Blackline Safety Enters into Definitive Agreement to be Acquired by Francisco Partners for up to $850 Million...
-
First Trust Global Funds PLC UK Regulatory Announcement: Net Asset Value(s)
LONDON--(BUSINESS WIRE)-- Funds Date TIDM ISIN Code Shares in Issue Currency Net Asset Value NAV/per Share First Trust United Kingdom AlphaDEX UCITS ETF 07.04.2026 FKU IE00B8X9NZ57 209,100.00 GBP 8,509,303.99 40.695 ...
-
Telia to Deploy Seamless OS Following Acquisition of Telness Operator
STOCKHOLM--(BUSINESS WIRE)--Telia becomes first MNO to deploy Seamless OS after acquiring Telness, marking a huge expansion of the BSS/OSS platform from Telness Tech...
-
Experian UK&I strengthens its leading digital verification capabilities with the addition of Konfir
LONDON--(BUSINESS WIRE)--Experian, the global data and technology company, has today announced the expansion of its verification capabilities in the UK with the addition of Konfir. Verification remains a challenge for many consumers during key life events. When confirming income or employment, or applying for finance, people are still required to complete checks that rely on slow, manual steps. These processes cause delays and disrupt the seamless digital experiences customers now expect. Konfi...
-
Precision BioSciences to Participate in the 25th Annual Needham Virtual Healthcare Conference
DURHAM, N.C.--(BUSINESS WIRE)--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for high unmet need diseases, today announced the Company will participate in the 25th Annual Needham Virtual Healthcare Conference being held April 13-16, 2026. 25th Annual Needham Virtual Healthcare Conference Format: Virtual Corporate presentation Date/Time: Tuesday, April 14, 2026 at 9:30am...
-
Oscar Mayer Unveils First Bacon Innovation in Five Years with New Maple Bourbon Bacon
CHICAGO & PITTSBURGH--(BUSINESS WIRE)--Today, Oscar Mayer, the brand known for uniting millions around a love of meat, announces its first bacon innovation in five years. Introducing Oscar Mayer Maple Bourbon Bacon—cured with Evan Williams Bourbon, the new offering features thick-cut, expertly trimmed bacon, finished with Oscar Mayer’s signature 12-hour slow smoke and subtle notes of vanilla and caramel from the barrel-aged Kentucky bourbon. Bringing together two iconic brands that are known fo...
-
FiscalNote Expands PolicyNote API with District Matching Capability to Power Organizations’ Grassroots Advocacy Efforts
WASHINGTON--(BUSINESS WIRE)--FiscalNote Expands PolicyNote API with District Matching Capability to Power Organizations’ Grassroots Advocacy Efforts...
-
Americhem Announces Expansion of Global Healthcare Footprint with New China Investment at Chinaplas 2026
CUYAHOGA FALLS, Ohio & SUZHOU, China--(BUSINESS WIRE)--Americhem, a global leader in polymer solutions, today announced an expansion of its healthcare capabilities with a new clean compounding facility in Suzhou, China, alongside the introduction of advanced material technologies at Chinaplas 2026. Scheduled to come online in the second half of 2026, the facility will be purpose-built to meet ISO 13485 and cGMP standards, extending Americhem’s healthcare manufacturing network into Asia and rein...
-
Bausch + Lomb Receives FDA 510(k) Clearance for Bi-Blade+™ Dual-Port Vitrectomy Cutter and Adaptive Fluidics™ Advanced Update
VAUGHAN, Ontario--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced that the U.S. Food and Drug Administration has granted 510(k) clearance for the Bi-Blade+ advanced dual-port vitrectomy cutter and the Adaptive Fluidics advanced update on the Stellaris Elite® Vision Enhancement System. “Retinal surgeons who are familiar with our Bi-Blade technology understand the benefits of it...
-
Sidewinder Therapeutics Announces $137 Million Series B Financing to Advance Precision Bispecific ADCs into Clinical Development for Cancer
SAN DIEGO--(BUSINESS WIRE)--Sidewinder Therapeutics, a biopharmaceutical company pioneering the development of next-generation bispecific ADCs (antibody-drug conjugates) for the treatment of cancer, today announced the closing of an oversubscribed $137 million Series B financing. The round was co-led by Frazier Life Sciences and Novartis Venture Fund, with participation from the sole Series A investor OrbiMed as well as new investors including Life Sciences at Goldman Sachs Alternatives, DCVC B...